Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDIZEM vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium influx into cardiac and vascular smooth muscle cells during depolarization by binding to L-type calcium channels. This results in coronary vasodilation, decreased myocardial oxygen demand, and negative chronotropic and inotropic effects.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Angina pectoris (chronic stable, vasospastic),Atrial fibrillation or atrial flutter (rate control),Hypertension
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Oral: 30-120 mg three to four times daily; extended-release: 120-360 mg once daily. IV: Initial 0.25 mg/kg (max 25 mg) bolus over 2 minutes, may repeat in 15 minutes (0.35 mg/kg); maintenance: 5-15 mg/hour continuous infusion.
Intravenous: 500 mg every 6 hours.
Terminal elimination half-life is 3.0-4.5 hours in healthy adults; may be prolonged to 7-9 hours in elderly, hepatic impairment, or renal impairment; clinically relevant for dosing frequency.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism; metabolites: desacetyl diltiazem (active, 40-50% potency), N-demethylated, and deacetylated forms.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Primarily hepatic metabolism with extensive first-pass effect; approximately 2-4% excreted unchanged in urine; fecal excretion accounts for about 65% of dose as metabolites; renal excretion accounts for about 35% of dose as metabolites.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
77-87% bound to plasma proteins, primarily albumin.
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
3-5 L/kg; large Vd indicates extensive tissue binding and distribution.
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Oral: 40-50% due to significant first-pass metabolism (range 30-60% across individuals); IV: 100%.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
No specific dose adjustment for renal impairment; use with caution in severe renal dysfunction (Cr Cl <30 m L/min) with close monitoring of heart rate and blood pressure.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh Class A: No adjustment. Class B: Reduce total daily dose by 25-50%. Class C: Avoid use; if necessary, consider further dose reduction with careful monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Oral: 1.5-2 mg/kg/day divided every 6-8 hours, maximum 3.5 mg/kg/day. Extended-release not recommended in children. IV: Use only with caution; dosing not well established; typical initial bolus 0.1-0.3 mg/kg over 2 minutes, maximum 10 mg; infusion 0.5-5 mcg/kg/min.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Start at lower end of dosing range: oral immediate-release 30 mg three times daily; extended-release 120 mg once daily. Increase slowly. IV: Lower initial bolus (0.15-0.2 mg/kg) and infusion rates (2-5 mg/hour). Monitor for hypotension and bradycardia.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
There is no FDA black box warning for CARDIZEM (diltiazem).
None
Symptomatic hypotension,Bradycardia or heart block (especially in sick sinus syndrome or AV block without pacemaker),Worsening heart failure in patients with reduced ventricular function,Hepatic injury (rare but elevated liver enzymes reported),Concomitant use with beta-blockers may increase risk of bradycardia and heart failure,Digitalis toxicity risk increased when used with digoxin,May exacerbate myasthenia gravis,Acute generalized exanthematous pustulosis (AGEP) and other severe cutaneous reactions,Gradual withdrawal recommended for chronic therapy to avoid angina exacerbation,May lower blood pressure, use with caution in patients with hypotension,Use in renal impairment: monitor carefully
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Hypersensitivity to diltiazem or any component,Sick sinus syndrome (except with functioning ventricular pacemaker),Second- or third-degree AV block (except with functioning pacemaker),Severe hypotension (systolic < 90 mm Hg),Acute myocardial infarction with pulmonary congestion,Atrial fibrillation or flutter associated with accessory bypass tract (e.g., WPW syndrome; risk of ventricular tachycardia or fibrillation),Cardiogenic shock,Concurrent use with ivabradine,Lactation (due to potential adverse effects in infants)
None
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase diltiazem levels, leading to toxicity. High-fat meals may increase absorption of some extended-release formulations; take with consistent meals. Alcohol may increase the risk of hypotension and dizziness. Maintain adequate hydration and avoid excessive salt intake to control blood pressure.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
No adequate studies in pregnant women. In animal studies, diltiazem (Cardizem) has been shown to cause skeletal abnormalities and increased fetal mortality at doses 5-10 times the maximum recommended human dose. Based on animal data and human experience with calcium channel blockers, risk cannot be ruled out. Use only if potential benefit justifies risk to fetus. Category C.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Diltiazem is excreted in human milk. A study reported a milk-to-plasma (M/P) ratio of approximately 0.9. The estimated infant dose is 1-2% of maternal weight-adjusted dose. Caution is advised; consider waiting 3-4 hours after dose before breastfeeding to minimize exposure.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
Increased plasma volume and altered protein binding in pregnancy may reduce diltiazem concentrations; consider dose titration based on clinical response. No specific dose adjustment established; monitor therapeutic effect.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
Cardizem (diltiazem) is a non-dihydropyridine calcium channel blocker used for hypertension, angina, and atrial fibrillation/atrial flutter. It is contraindicated with IV beta-blockers due to risk of bradycardia and heart block. In AF, use IV form for rate control but avoid in WPW due to risk of ventricular pre-excitation. Diltiazem is metabolized by CYP3A4; caution with strong inhibitors like clarithromycin or grapefruit juice. For hypertension, start at 30 mg TID or extended-release once daily. Monitor heart rate and PR interval; avoid in sick sinus syndrome or second/third-degree AV block without pacemaker.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take this medication exactly as prescribed; do not crush or chew extended-release capsules.,Avoid grapefruit and grapefruit juice while taking this medication.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.,Do not stop taking this medication abruptly, as it may worsen your condition.,Common side effects include dizziness, headache, and swelling in the ankles/feet; contact your doctor if you experience slow heartbeat, shortness of breath, or fainting.,This medication may cause dizziness or lightheadedness; avoid driving or operating machinery until you know how it affects you.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDIZEM vs AMVAZ, answered by our medical review team.
CARDIZEM is a Calcium Channel Blocker that works by Diltiazem inhibits calcium influx into cardiac and vascular smooth muscle cells during depolarization by binding to L-type calcium channels. This results in coronary vasodilation, decreased myocardial oxygen demand, and negative chronotropic and inotropic effects.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDIZEM and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDIZEM is: Oral: 30-120 mg three to four times daily; extended-release: 120-360 mg once daily. IV: Initial 0.25 mg/kg (max 25 mg) bolus over 2 minutes, may repeat in 15 minutes (0.35 mg/kg); maintenance: 5-15 mg/hour continuous infusion.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDIZEM and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDIZEM is classified as Category C. No adequate studies in pregnant women. In animal studies, diltiazem (Cardizem) has been shown to cause skeletal abnormalities and increased fetal mortality at doses 5-10 times the . AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.